We’ve talked about drug delivery company Starpharma (OTC: SPHRY) for some time in Portfolio 2020 and its progenitor New World 3.0. The stock is up about 300 percent over the past 12 months, and it’s about time we add it to the portfolio.

Although the stock has done quite well, there’s still plenty of upside left and it’s positioned now to really make some noise.

In a recent article on drug delivery stocks, we discussed Starpharma’s promise–its leading position in dendrimer manufacturing, its laundry list of high-powered partnerships and its exciting anti-STD and spermicide, VivaGel.

A recent article in New Scientist reported that another anti-HIV gel has failed a large trial and two others may be suffering similar problems. HIV vaccines are in development but are years from reaching the market. Starpharma is still one of the only players successfully navigating drug trials.

What’s more, even if VivaGel fails to obtain approval for its anti-HIV qualities, the company has already proven that the product is a more effective spermicide than nonoxynol-9 and very effective against HPV and herpes transmission. Starpharma has a unique delivery system and isn’t attempting to concoct a drug so much as an effective form of protection.

There’s plenty to like here–and plenty of big drug, chemical and health care companies that might be interested in adding Starpharma and its innovations to their stable. Even without an acquisition, Starpharma has proven it can make it on its own. Buy Starpharma gradually between 5 and 5.75, and more aggressively on pullbacks below 5.